Innovative Liquid Biopsy Assay Approved by Highmark

Over the years, finding easier and more effective ways to identify appropriate treatments for non-small cell lung cancer (NSCLC) patients has been a major focus for liquid biopsy developers. After more than two years of diagnostic evaluation, Biocept’s Target Selector liquid biopsy assay was approved by health insurance carrier, Highmark. …